Breaking News

Fujifilm Investing $1.6B to Expand Cell Culture Manufacturing Services

Will enhance Fujifilm Diosynth Biotechnologies’ sites in Hillerød, Denmark, and Texas in the U.S.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Fujifilm Corporation has unveiled plans to invest $1.6 billion to enhance and expand the cell culture manufacturing services of Fujifilm Diosynth Biotechnologies, a subsidiary of Fujifilm Corporation, and global contract development and manufacturing organization (CDMO). This investment will enhance Fujifilm Diosynth Biotechnologies’ sites in Hillerød, Denmark, and Texas in the U.S. As part of this investment, Fujifilm Diosynth Biotechnologies is expanding its capacity to support large-scale ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters